N5334 Final LATEST 2026/2027
ACTUAL EXAM| PHARM EXAM 3
REVIEW WITH COMPLETE REAL
EXAM QUESTIONS AND CORRECT
DETAILED ANSWERS (VERIFIED
ANSWERS) ALREADY GRADED A+
Prescribingmbasicsm-mCORRECTmANSWERmPrescribingmismregulatedmbymstatemBON
PropermRXm-mCORRECTmANSWERmProvidersmnamemandmaddress,mTelephone
DEA
Ptmname/DOB/Addres
NamemofmDrug,mstrength,mSIG(directions)mwithmindication/Routemandmfrequency,mQuantitymandmsi
gnature.
DrugmSchedules:mMostmaddictivemtomleastm-mCORRECTmANSWERm1:mHeroin,LSD,mMJ
2:mhydrocodone,mcocaine,mMethamphetamine,mmethadone,moxycodone,mmeperidine,mfentanyl,m
adderall,mritalin
3:mcodeine,mketamine,mtestosterone
4:mxanax,mvalium,msoma,mambient,mtramadol
5:mantidiarrheal,mantitussives,mlomotil,mlyrica
Pharmicodyamicsm-
mCORRECTmANSWERmThemeffectsmofmdrugmonmthembody.mReceptorsmaremlargemmoleculesmusuallymp
roteins,mthatminteractmandmmediatemthemactionmofmdrugs
,agonistm-
mCORRECTmANSWERmproducemreceptormstimulationmandmamconformationalmchangemeverymtimemth
eymbind.mDomnotmneedmallmavailablemreceptorsmtomproducemammaximummresponse
Partialmagonistm-
mCORRECTmANSWERmdrugsmthatmhavempropertiesminmb/wmthosemofmfullmagonistmandmantagonist.mT
heymbindmtomreceptorsmbutmwhenmtheymoccupymthemreceptormsites,mtheymstimulatemonlymsomemofm
themreceptors.
antagonistm-
mCORRECTmANSWERmdrugsmwithmaffinitymformamreceptormbutmwithmnomintrinsicmactivity.mAffinitymall
owsmthemantagonistmtombindmtomreceptors,mbutmlackmofmintrinsicmactivitympreventsmthemboundmant
agonistmfrommcausingmreceptormactivation.mThemblockmactionmofmdrugsm(ex.mNarcan)
Bioavailabitym-
mCORRECTmANSWERm%mofmadministeredmdosagemofmthemdrugmthatmsurvivesmthemfirstmpassmthroug
hmthemlivermandmreachesmthembloodmstream
halfmlifem-
mCORRECTmANSWERmTimemrequiredmformthemamountmofmamdrugminmthembodymtomdeclinembym50%,m
drugsmwithmshortermhalfmlivesmmustmbemadministermfrequently.m4.5-
5.5mtimesmthemhalfmlifemtomgetmsteadymstatemandmtombemlimitedmfrommthembody
whatmthembodymdoesmtomthemdrugm-
mCORRECTmANSWERmabsorption,mdistribution,mmetabolism,mexcretion
Distributionm-
mCORRECTmANSWERmmovementmofmabsorbedmdrugminmbodilymfluidsmthroughoutmthembodymtomtar
getmtissue.mPropertiesmaffecting:mlipid/watermsolubility,mPHmaffectsmionizationmofmdrug,mproteinmbi
nding,msizemofmmoleculem(smallermmoleculesmaremmoremablemtomdiffuse)
,Tissue:mfat,mbone,mblood/brainmbarrierm(onlymlipidmsolublemwillmpass),mplacentalmbarrierm(manymdr
ugsmcanmpass)
Proteinmbindingm-
mCORRECTmANSWERmunboundmdrugmismfreemwhichmismactive,mcrossesmmembrane.mLowmplasmampr
oteinsmresultminmmoremfreemdrug.mCompetition:mwhenm2mhighlymboundmdrugsmaremgivenmitmincreas
esmthemlevelmofmbothmdrugs
Metabolismm-
mCORRECTmANSWERmtakemplaceminmthemlivermmostly.mChemicalmchangemofmamdrugmstructuremto:m
Enhancemexcretion,minactivatemthemdrug,mincreasemtherapeuticmaction,mactivemamprodrugm(inactive
muntilmmetabolizedminmthembodymintomthemactivemcompound,mex:mlevodopa),mincreasemormdecrease
mtoxicity
CYP450m-
mCORRECTmANSWERmenzymesmconstitutesmthemmostmimportantmofmthemphasemImmetabolizingmenz
ymesm(accountmformaboutm75%mofmdrugmmetabolismminmthemliver)
Phasem2:mconjugationmreactionmoccurmleadingmtomlargemincreasesminmhydrophilicitymofmthemsubstra
tesmrenderingmthemmmoremreadilymexcretable
Substratem-
mCORRECTmANSWERmanmagentmthatmismmetabolizedmbymanmenzymemintomammetabolitemandmprodu
ctmandmeventuallymexcreted
Inhibitorsm-
mCORRECTmANSWERmcompetemwithmothermdrugsmformamparticularmenzymemaffectingmthemmetaboli
smm(decreased)mofmthemsubstratemandmdecreasesmthemexcretionmofmthemsubstratemandmincreasingm
themcirculatingmdrug
, inducerm-
mCORRECTmANSWERmcompetesmwithmothermdrugsmformamparticularmenzymemaffectingmmetabolism
mofmthemsubstratem(increases)mdecreasingmthemefficacymofmthemdrug
excretionm-
mCORRECTmANSWERmrenal:mpassivemglomerularmfiltration,mactivemtubularmsecretion,mtubularmreab
sorption,mgimtract,mlung,msweatmandmsalivary,mmammary
genomicsm-
mCORRECTmANSWERmstudymofmthemcompletemsetmofmgeneticminformationmpresentminmamcell,manmor
ganism,mormspecies
pharmacogeneticsm-
mCORRECTmANSWERmthemstudymofmtheminfluencemofmhereditarymfactorsmonmthemresponsemofmindivi
dualmorganismsmtomdrugs,mandmthemstudymofmvariationsmofmDNAmandmRNAmcharacteristicsmasmrelat
edmtomdrugmresponse
Pharmacogeneticsmtestsm-
mCORRECTmANSWERmMentionedmonmdrugmlabelsmcanmbemclassifiedmasm"testmrequired,"m"testmreco
mmended,"mandm"informationmonly."mCurrently,mfourmdrugsmaremrequiredmtomhavempharmacogen
eticsmtestingmperformedmbeforemtheymaremprescribed:mcetuximab,mtrastuzumab,mmaravirocmandmd
asatinib
wafarin,mcarbamazepine,mvalproicmacidmandmabacavirmaremrecommendedmtomtestsmpriormtominitialm
dosing
CarbamazepinemandmAsisansm-
mCORRECTmANSWERmInitiatingmcarbamazepinemtherapyminmthesempatientsm(allelemHLA-
B*1502)marematmhighmriskmformdevelopingmStevenmJohnsonmsyndromemormtoxicmepidermalmnecroly
sism(TEN)
ACTUAL EXAM| PHARM EXAM 3
REVIEW WITH COMPLETE REAL
EXAM QUESTIONS AND CORRECT
DETAILED ANSWERS (VERIFIED
ANSWERS) ALREADY GRADED A+
Prescribingmbasicsm-mCORRECTmANSWERmPrescribingmismregulatedmbymstatemBON
PropermRXm-mCORRECTmANSWERmProvidersmnamemandmaddress,mTelephone
DEA
Ptmname/DOB/Addres
NamemofmDrug,mstrength,mSIG(directions)mwithmindication/Routemandmfrequency,mQuantitymandmsi
gnature.
DrugmSchedules:mMostmaddictivemtomleastm-mCORRECTmANSWERm1:mHeroin,LSD,mMJ
2:mhydrocodone,mcocaine,mMethamphetamine,mmethadone,moxycodone,mmeperidine,mfentanyl,m
adderall,mritalin
3:mcodeine,mketamine,mtestosterone
4:mxanax,mvalium,msoma,mambient,mtramadol
5:mantidiarrheal,mantitussives,mlomotil,mlyrica
Pharmicodyamicsm-
mCORRECTmANSWERmThemeffectsmofmdrugmonmthembody.mReceptorsmaremlargemmoleculesmusuallymp
roteins,mthatminteractmandmmediatemthemactionmofmdrugs
,agonistm-
mCORRECTmANSWERmproducemreceptormstimulationmandmamconformationalmchangemeverymtimemth
eymbind.mDomnotmneedmallmavailablemreceptorsmtomproducemammaximummresponse
Partialmagonistm-
mCORRECTmANSWERmdrugsmthatmhavempropertiesminmb/wmthosemofmfullmagonistmandmantagonist.mT
heymbindmtomreceptorsmbutmwhenmtheymoccupymthemreceptormsites,mtheymstimulatemonlymsomemofm
themreceptors.
antagonistm-
mCORRECTmANSWERmdrugsmwithmaffinitymformamreceptormbutmwithmnomintrinsicmactivity.mAffinitymall
owsmthemantagonistmtombindmtomreceptors,mbutmlackmofmintrinsicmactivitympreventsmthemboundmant
agonistmfrommcausingmreceptormactivation.mThemblockmactionmofmdrugsm(ex.mNarcan)
Bioavailabitym-
mCORRECTmANSWERm%mofmadministeredmdosagemofmthemdrugmthatmsurvivesmthemfirstmpassmthroug
hmthemlivermandmreachesmthembloodmstream
halfmlifem-
mCORRECTmANSWERmTimemrequiredmformthemamountmofmamdrugminmthembodymtomdeclinembym50%,m
drugsmwithmshortermhalfmlivesmmustmbemadministermfrequently.m4.5-
5.5mtimesmthemhalfmlifemtomgetmsteadymstatemandmtombemlimitedmfrommthembody
whatmthembodymdoesmtomthemdrugm-
mCORRECTmANSWERmabsorption,mdistribution,mmetabolism,mexcretion
Distributionm-
mCORRECTmANSWERmmovementmofmabsorbedmdrugminmbodilymfluidsmthroughoutmthembodymtomtar
getmtissue.mPropertiesmaffecting:mlipid/watermsolubility,mPHmaffectsmionizationmofmdrug,mproteinmbi
nding,msizemofmmoleculem(smallermmoleculesmaremmoremablemtomdiffuse)
,Tissue:mfat,mbone,mblood/brainmbarrierm(onlymlipidmsolublemwillmpass),mplacentalmbarrierm(manymdr
ugsmcanmpass)
Proteinmbindingm-
mCORRECTmANSWERmunboundmdrugmismfreemwhichmismactive,mcrossesmmembrane.mLowmplasmampr
oteinsmresultminmmoremfreemdrug.mCompetition:mwhenm2mhighlymboundmdrugsmaremgivenmitmincreas
esmthemlevelmofmbothmdrugs
Metabolismm-
mCORRECTmANSWERmtakemplaceminmthemlivermmostly.mChemicalmchangemofmamdrugmstructuremto:m
Enhancemexcretion,minactivatemthemdrug,mincreasemtherapeuticmaction,mactivemamprodrugm(inactive
muntilmmetabolizedminmthembodymintomthemactivemcompound,mex:mlevodopa),mincreasemormdecrease
mtoxicity
CYP450m-
mCORRECTmANSWERmenzymesmconstitutesmthemmostmimportantmofmthemphasemImmetabolizingmenz
ymesm(accountmformaboutm75%mofmdrugmmetabolismminmthemliver)
Phasem2:mconjugationmreactionmoccurmleadingmtomlargemincreasesminmhydrophilicitymofmthemsubstra
tesmrenderingmthemmmoremreadilymexcretable
Substratem-
mCORRECTmANSWERmanmagentmthatmismmetabolizedmbymanmenzymemintomammetabolitemandmprodu
ctmandmeventuallymexcreted
Inhibitorsm-
mCORRECTmANSWERmcompetemwithmothermdrugsmformamparticularmenzymemaffectingmthemmetaboli
smm(decreased)mofmthemsubstratemandmdecreasesmthemexcretionmofmthemsubstratemandmincreasingm
themcirculatingmdrug
, inducerm-
mCORRECTmANSWERmcompetesmwithmothermdrugsmformamparticularmenzymemaffectingmmetabolism
mofmthemsubstratem(increases)mdecreasingmthemefficacymofmthemdrug
excretionm-
mCORRECTmANSWERmrenal:mpassivemglomerularmfiltration,mactivemtubularmsecretion,mtubularmreab
sorption,mgimtract,mlung,msweatmandmsalivary,mmammary
genomicsm-
mCORRECTmANSWERmstudymofmthemcompletemsetmofmgeneticminformationmpresentminmamcell,manmor
ganism,mormspecies
pharmacogeneticsm-
mCORRECTmANSWERmthemstudymofmtheminfluencemofmhereditarymfactorsmonmthemresponsemofmindivi
dualmorganismsmtomdrugs,mandmthemstudymofmvariationsmofmDNAmandmRNAmcharacteristicsmasmrelat
edmtomdrugmresponse
Pharmacogeneticsmtestsm-
mCORRECTmANSWERmMentionedmonmdrugmlabelsmcanmbemclassifiedmasm"testmrequired,"m"testmreco
mmended,"mandm"informationmonly."mCurrently,mfourmdrugsmaremrequiredmtomhavempharmacogen
eticsmtestingmperformedmbeforemtheymaremprescribed:mcetuximab,mtrastuzumab,mmaravirocmandmd
asatinib
wafarin,mcarbamazepine,mvalproicmacidmandmabacavirmaremrecommendedmtomtestsmpriormtominitialm
dosing
CarbamazepinemandmAsisansm-
mCORRECTmANSWERmInitiatingmcarbamazepinemtherapyminmthesempatientsm(allelemHLA-
B*1502)marematmhighmriskmformdevelopingmStevenmJohnsonmsyndromemormtoxicmepidermalmnecroly
sism(TEN)
